Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18393361 | 0.81 | CA2 (0.46) | CA2CA4CA1CA6MAPT | |
| SCHEMBL6410058 | 0.72 | HSD17B10 (0.50) | CA2CA4CA1CA6MAPT | |
| SCHEMBL3927720 | 0.72 | MAPT (0.46) | CA2CA4CA1CA6MAPT | |
| SCHEMBL16240772 | 0.72 | MAPT (0.46) | MAPTSHBGGFERALDH1A1PDE4A | |
| SCHEMBL30679916 | 0.72 | ALOX5 (0.47) | CA2CA1MAPTSHBGALOX15 | |
| SCHEMBL8797591 | 0.72 | ALOX5 (0.47) | CA2CA1MAPTSHBGALOX15 | |
| SCHEMBL14507727 | 0.71 | CA2 (0.61) | CA2CA4CA1CA6MAPT | |
| SCHEMBL5143316 | 0.70 | ERN1 (0.51) | CA2CA1MAPTTPMT | |
| SCHEMBL28111225 | 0.70 | CA2 (0.46) | CA2CA4CA1CA6MAPT | |
| Methoxymethane SCHEMBL11333003 | 0.69 | TPMT (0.46) | CA2CA4CA1CA6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007095630-A2 | NEW UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095630-A2 | NEW UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095631-A2 | NEW DRUG DELIVERY SYSTEM FOR CROSSING THE BLOOD BRAIN BARRIER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095631-A2 | NEW DRUG DELIVERY SYSTEM FOR CROSSING THE BLOOD BRAIN BARRIER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | NDUFB7, NDUFB1, NDUFB3 | CA2 4679/4885CA4 4514/4885CA1 4571/4885 |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | NDUFB5, NDUFB7, NDUFB3 | CA2 4133/4885CA4 4329/4885CA1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.